Gastric Cancer- Pipeline Insight, 2025

This “Gastric Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Gastric Cancer: Understanding

Gastric Cancer: Overview

Gastric cancer, also known as stomach cancer, arises from the lining of the stomach. It is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths. The majority of gastric cancers are adenocarcinomas, which develop from the mucus-producing cells of the stomach lining. Risk factors include chronic gastritis, Helicobacter pylori infection, smoking, a diet high in salty and smoked foods, and genetic predispositions. Signs and symptoms of gastric cancer are often non-specific and may include weight loss, abdominal pain, nausea, vomiting, dysphagia (difficulty swallowing), early satiety (feeling full quickly), and melena (black, tarry stools indicating bleeding in the stomach). These symptoms often appear late in the disease, which is why gastric cancer is frequently diagnosed at an advanced stage.

The exact cause of gastric cancer is multifactorial. Chronic infection with H. pylori is a significant risk factor, leading to chronic inflammation and changes in the gastric mucosa that can progress to cancer. Genetic factors also play a role, with conditions like hereditary diffuse gastric cancer syndrome increasing risk. Environmental factors such as smoking, diet, and occupational exposure to certain chemicals also contribute.

Pathophysiologically, gastric cancer development involves a multistep process starting from chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and finally carcinoma. The interaction between genetic mutations and environmental factors leads to uncontrolled cell growth and tumor formation. Molecular changes such as alterations in the p53 gene, E-cadherin gene mutations, and other oncogene and tumor suppressor gene mutations are involved in the progression of the disease. Diagnosis of gastric cancer typically involves endoscopic examination and biopsy of suspicious lesions. Imaging studies such as CT scans, PET scans, and endoscopic ultrasound help in staging the disease. Treatment options depend on the stage of the cancer and may include surgery, chemotherapy, radiation therapy, and targeted therapy. Early-stage cancers may be treated with endoscopic resection or partial gastrectomy, while advanced cases often require a combination of treatments to manage the disease and improve quality of life. Immunotherapy has also shown promise in certain types of gastric cancer. Early detection and treatment are crucial for improving survival rates.  

'Gastric Cancer- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gastric Cancer.

Gastric Cancer Emerging Drugs Chapters

This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastric Cancer Emerging Drugs

Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. The China National Medical Products Administration (NMPA) has approved tislelizumab in six indications. Including full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, for first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and for second- or third-line treatment of patients with locally advanced or metastatic NSCLC who progressed on prior platinum-based chemotherapy. Tislelizumab is not approved for use outside of China. Currently the drug is registered for the treatment of gastric cancer.

Catumaxomab: Linton Pharm Co. Ltd.

Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. Currently the drug is in Phase III stage of development for the treatment of gastric cancer.

Tivumecirnon: RAPT Therapeutics

Tivumecirnon is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues. Treg represent a dominant pathway for downregulating the immune response, generally correlate with poor clinical outcomes and may limit the effectiveness of currently available therapies such as checkpoint inhibitors. Tivumecirnon may restore naturally occurring antitumor immunity alone and may synergize with a variety of both conventional and immune-based therapies, such as radiation, chemotherapy, checkpoint inhibitors, immune stimulators, cancer vaccines and adoptive T cell therapy. Currently the drug is in Phase II stage of development for the treatment of gastric cancer.

DKN-01: Leap Therapeutics

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling, a signaling pathway frequently implicated in tumorigenesis and suppressing the immune system. DKK1 has an important role in tumor cell signaling and in mediating an immuno-suppressive tumor microenvironment through enhancing the activity of myeloidderived suppressor cells and downregulating NK ligands on tumor cells. DKN-01 has received Orphan Drug Designation for the treatment of gastric and gastroesophageal junction cancer from the U.S. Food and Drug Administration. Currently the drug is in Phase II stage of development for the treatment of gastric cancer.

Venadaparib: Idience

Venadaparib (IDX-1197) is a potent PARP inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promote the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells. IDX-1197 is under clinical development targeting multiple solid tumors as a monotherapy (including maintenance) and for combination with other anti-cancer agents. Currently the drug is in Phase I stage of development for the treatment of gastric cancer.

BDC-4182: Bolt Biotherapeutics

BDC-4182 is Bolt’s next-generation ISAC candidate targeting Claudin 18.2, a novel target in oncology, with programs in development for the treatment of gastric or gastroesophageal junction cancer and pancreatic cancer. Currently the drug is in Preclinical stage of development for the treatment of gastric cancer.

Gastric Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastric Cancer

There are approx. 200+ key companies which are developing the therapies for Gastric Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. Phase III include, BeiGene.

Phases

The report covers around 220+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastric Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.

Gastric Cancer Report Insights

• Gastric Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gastric Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastric Cancer drugs?
• How many Gastric Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastric Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BeiGene
• Linton Pharm Co. Ltd.

RAPT Therapeutics

• Leap Therapeutics
• Idience
• Bolt Biotherapeutics
• Hubro Therapeutics
• Immunocore
• Ambrx
• Hangzhou DAC Biotech
• Beijing Immunoah Pharma Tech
• Base Therapeutics
• Nanjing KAEDI Biotech
• HiberCell
• Transcenta Holding
• Suzhou Zelgen Biopharmaceuticals
• Daiichi Sankyo
• Ipsen
• Alligator Bioscience
• Bristol Myers Squibb
• Jiangsu Hengrui Medicine
• Shanghai Junshi Biosciences
• ImmunoACT

Key Products

• Tislelizumab
• Catumaxomab
• Tivumecirnon
• DKN-01
• Venadaparib
• BDC-4182
• FMPV-1
• IMC R117C
• ARX 788
• DX126 262
• ZWB 67
• NK 510
• KD 496
• HC 5404
• Osemitamab
• Donafenib
• Datopotamab deruxtecan
• Irinotecan sucrosofate
• HLX 22
• Ipilimumab
• Retlirafusp alfa
• Toripalimab
• HCAR 4

This product will be delivered within 3-5 business days.